[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 16, 1980

The Case for Boards in Clinical Pharmacology

Author Affiliations

From the Office of the Vice-President and Dean, The Hahnemann Medical College & Hospital, Philadelphia.

JAMA. 1980;243(19):1918-1920. doi:10.1001/jama.1980.03300450032017
Abstract

THERE is an intense and active debate concerning the need for board certification among the three major societies that represent clinical pharmacology. In fact, a task force composed of members of the American College of Clinical Pharmacology (ACCP), the American Society for Clinical Pharmacology and Therapeutics (ASCPT), and the Clinical Pharmacology Division of the American Society for Pharmacology and Experimental Therapeutics (ASPET) is now at work to resolve this problem. The need to address this problem has arisen because the American Board of Clinical Pharmacology was actually incorporated in August 1976 by a group of distinguished clinical pharmacologists. This board has the moral support of the ACCP but is independent of the three societies. The board has agreed to delay its first examination and confirmation to the American Board of Medical Specialists until the task force has completed its deliberations.

It is pertinent to restate here the reasoning, the pros

×